Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21863534 | 0.89 | DRD2 (0.37) | DRD2DRD4DRD3NOS3NOS1 | |
| SCHEMBL26782831 | 0.85 | HPGD (0.40) | DRD2DRD4DRD3NOS3NOS1 | |
| SCHEMBL17047825 | 0.85 | AADAT (0.39) | DRD2DRD4DRD3NOS3NOS1 | |
| SCHEMBL22648242 | 0.81 | GABRA1 (0.44) | — | |
| SCHEMBL5021276 | 0.81 | GAA (0.46) | DRD2DRD4DRD3AXL | |
| SCHEMBL5021087 | 0.81 | LRRK2 (0.41) | DRD2DRD4DRD3AXL | |
| Hydrochloric Acid SCHEMBL15995690 | 0.79 | GAA (0.45) | DRD2DRD4DRD3AXL | |
| SCHEMBL5020950 | 0.78 | DRD2 (0.32) | DRD2DRD4DRD3 | |
| SCHEMBL22648295 | 0.77 | DRD2 (0.45) | DRD2DRD4DRD3AXL | |
| SCHEMBL30267100 | 0.77 | DRD2 (0.36) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815882-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | DRD2 632/4885DRD4 1366/4885DRD3 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.